Paper18192510
Efficacy and safety of the Gardos channel blocker, senicapoc (ICA-17043), in patients with sickle cell anemia.
Ataga KI and 11 others. Blood, 2008. Cited by 191 papers, by iCite.
Cite this record
ConductScience Library. Efficacy and safety of the Gardos channel blocker, senicapoc (ICA-17043), in patients with sickle cell anemia. Papers, record 18192510. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/18192510
- Disease
- sickle cell disease163 drugs
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Connected records1
Records in the library's other databases whose lists name this one, each read from that database's own release: up to 20 of each kind, the most connected first.
Topics12
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Acetamides | Major topic |
| Anemia, Sickle Cell | Major topic |
| Potassium Channel Blockers | Major topic |
| Triphenylmethyl Compounds | Major topic |
| Adolescent | |
| Adult | |
| Female | |
| Humans | |
| Male | |
| Middle Aged | |
| Time Factors | |
| Treatment Outcome |
Source PubMed
Trials1
The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.
| Trial | Title | The trial lists it as | Named in the paper's record |
|---|---|---|---|
| NCT00040677 | A Study of the Efficacy and Safety of ICA-17043 (With or Without Hydroxyurea) in Patients With Sickle Cell Anemia. | Results | Yes |
Source ClinicalTrials.gov
Comments and corrections1
PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.
| Kind | PMID | Title | In Papers |
|---|---|---|---|
| Comment in | 18434967 | Gardos pathway to sickle cell therapies? | https://conductscience.org/library/papers/18434967 |
Source PubMed
Cited by129
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 191 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42979167 | Emerging and Repurposed Immune System Modulators for Alzheimer's Disease. | Drug Des Devel Ther | 2026 | https://conductscience.org/library/papers/42979167 | PubMed |
| 42547963 | Potassium Channels of the Airway Epithelium. | Acta Physiol (Oxf) | 2026 | https://conductscience.org/library/papers/42547963 | PubMed |
| 42279523 | Senicapoc in Patients with Idiopathic Pulmonary Fibrosis or Other Progressive Fibrotic Interstitial Lung Diseases: Protocol for a Randomised, Double-Blind, Placebo-Controlled, Multicentre Phase II Trial. | Diagnostics (Basel) | 2026 | https://conductscience.org/library/papers/42279523 | PubMed |
| 42206270 | Sickle Cell Hepatic Vaso-Occlusive Crisis: A Case Report. | Case Rep Hematol | 2026 | https://conductscience.org/library/papers/42206270 | PubMed |
| 41981510 | SENIPERA Phase 0/1 randomized window-of-opportunity clinical trial of SENIcapoc and PERAmpanel mono- and combination therapy of newly diagnosed glioblastoma: a trial protocol. | BMC Cancer | 2026 | https://conductscience.org/library/papers/41981510 | PubMed |
| 41827850 | The KCa3.1 K+ Channel and Cardiovascular Disease: An Upstream Target Linking Inflammation, Fibrosis and Electrical Instability. | Cells | 2026 | https://conductscience.org/library/papers/41827850 | PubMed |
| 41596371 | Hereditary Spherocytosis: Linking Ion Transport Defects to Osmotic Gradient Ektacytometry Profiles-A Review. | Int J Mol Sci | 2026 | https://conductscience.org/library/papers/41596371 | PubMed |
| 41531666 | MeMAGEN: A Phase IIa/IIb open-label trial of memantine testing safety and tolerability in sickle cell patients. | Hemasphere | 2026 | https://conductscience.org/library/papers/41531666 | PubMed |
| 41122971 | Kcnn4/KCa3.1 inhibition blunts polycystic kidney disease progression in mouse models. | JCI Insight | 2025 | https://conductscience.org/library/papers/41122971 | PubMed |
| 41059931 | Targeting PIEZO1-TMEM16F Coupling to Mitigate Sickle Cell Disease Complications. | Am J Hematol | 2025 | https://conductscience.org/library/papers/41059931 | PubMed |
| 41037639 | Enhanced PIEZO1 function contributes to the pathogenesis of sickle cell disease. | Proc Natl Acad Sci U S A | 2025 | https://conductscience.org/library/papers/41037639 | PubMed |
| 40304011 | What interval of daily pain assessment is required to reliably diagnose chronic pain in SCD? The Pain in Sickle Cell Epidemiology Study. | J Sick Cell Dis | 2024 | https://conductscience.org/library/papers/40304011 | PubMed |
| 38650890 | Entry inhibitors as arenavirus antivirals. | Front Microbiol | 2024 | https://conductscience.org/library/papers/38650890 | PubMed |
| 38522095 | Successes and pitfalls in orphan drug development for sickle cell disease. | Blood Adv | 2024 | https://conductscience.org/library/papers/38522095 | PubMed |
| 38406513 | A novel composition of endogenous metabolic modulators improves red blood cell properties in sickle cell disease. | EJHaem | 2024 | https://conductscience.org/library/papers/38406513 | PubMed |
| 38270470 | Exploring unconventional attributes of red blood cells and their potential applications in biomedicine. | Protein Cell | 2024 | https://conductscience.org/library/papers/38270470 | PubMed |
| 38136613 | Hypoxia, Ion Channels and Glioblastoma Malignancy. | Biomolecules | 2023 | https://conductscience.org/library/papers/38136613 | PubMed |
| 37890140 | The challenge of clinical end points in sickle cell disease. | Blood | 2023 | https://conductscience.org/library/papers/37890140 | PubMed |
| 37367787 | Role of Calcium-Activated Potassium Channels in Proliferation, Migration and Invasion of Human Chronic Myeloid Leukemia K562 Cells. | Membranes (Basel) | 2023 | https://conductscience.org/library/papers/37367787 | PubMed |
| 37125772 | The exocyst complex is required for the trafficking and delivery of KCa3.1 to the basolateral membrane of polarized epithelia. | Am J Physiol Cell Physiol | 2023 | https://conductscience.org/library/papers/37125772 | PubMed |
Drugs1
The drugs whose trials, in the Pipelines release, list the paper.
| Drug | ChEMBL ID | The trials list it as | Trials | In Drugs and targets |
|---|---|---|---|---|
| SENICAPOC | CHEMBL405821 | Results | 1 | https://conductscience.org/library/drugs/CHEMBL405821 |
Source ChEMBL
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- References
- Genes
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/18192510
GET https://conductscience.org/api/papers/v1/18192510/cited_by?page=2